http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2817779-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a708524c0adee3eb5b130dac053f9c3d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01R33-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-143333 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N24-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01R33-46 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N24-08 |
| filingDate | 2011-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0074a455fb93015a47fdc3cae2da5ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b08a0fe1ca8482b1b3ae11cb6b7c9984 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d30d600d236b62b35f9dd5ed41fc265 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ce32cc182c3d980791d73d33f0bc956 |
| publicationDate | 2021-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2817779-T3 |
| titleOfInvention | Evaluation of heparin preparations |
| abstract | A procedure to identify whether a procedure including oxidation or oxidation followed by treatment with an acid was used to make a heparin sample, comprising: determining whether a structural signature is absent or present in a heparin sample and / or determining the amount of the structural signature in the heparin sample, where the absence or presence of the structural signature is determined using nuclear magnetic resonance (NMR), where the presence of the structural signature and / or the presence in an amount indicates that the heparin sample it was made by a procedure and the absence of the structural signature indicates that the heparin sample was not made by the procedure; and perform a step with respect to the heparin sample if the heparin sample was made by the procedure, where the step is one or more of processing in a pharmaceutical product, shipping, formulation, labeling, packaging, marketing, sale and offer for the sale of the heparin sample; where the structural signature is one or more of: ** (See formula) ** where in structure B, X = H or SO3. |
| priorityDate | 2010-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 64.